RELATIONSHIP OF CYTOKINES TO COGNITIVE FUNCTIONS IN HEPATITIS C

丙型肝炎细胞因子与认知功能的关系

• 批准号: 7718737
• 负责人: ROBIN C HILSABECK
• 金额: $ 0.01万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7718737
• 关键词: Address; Aftercare; Antiviral Therapy; Attention; Biological Assay; Computer Retrieval of Information on Scientific Projects Database; Computer information processing; Condition; Data; Deoxyglucose; Etiology; Functional Magnetic Resonance Imaging; Funding; Grant; Hepatitis; Immune; Immune system; Impaired cognition; Institution; Interferon-alpha; Intervention; Lead; Learning; Magnetic Resonance Imaging; Measures; Memory; Neuraxis; Neuropsychological Tests; Participant; Patient Care; Patients; Positron-Emission Tomography; Research; Research Design; Research Personnel; Resolution; Resources; Rest; Role; Serum; Source; Testing; Toxicology; United States National Institutes of Health; Urine; Week; clinically relevant; cognitive function; cytokine; executive function; neuroimaging; neuropsychological; prospective; psychological distress; theories; time interval

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. OBJECTIVE: The central hypothesis of this study is that IFN-alpha is a key determinant of cognitive dysfunction observed in CHC patients. This hypothesis will be tested by addressing the following two specific aims: Specific Aim 1: To test the hypothesis that higher levels of IFN-alpha in serum are associated with cognitive dysfunction in CHC patients as measured by neuropsychological tests. Specific Aim 2: To test the hypothesis that higher levels of IFN-alpha in serum are associated with abnormalities in frontal-subcoritcal networks as measured by neuroimaging. RESEARCH PLAN: This is a prospective, repeated measures study design involving 40 CHC patients and 20 healthy control (HC) participants. CHC patients beginning antiviral therapy with IFN-alpha will be assessed at baseline (within one month of their first treatment), after 12, 24, and 48 weeks of therapy, and six months after treatment is stopped (regardless of when it was stopped). HC participants will undergo the same assessments as CHC patients at the same time intervals. METHODS: Urine toxicology screen, cytokine assays, psychiatric assessment (SCID-I), neuropsychological assessment (attention-executive functioning, information processing/psychomotor, learning/memory, effort and psychological distress), neuroimaging (MRI, high resolution structural MRI, resting-state fMRI, DTI [F]deoxyglucose positron emission tomography). CLINICAL RELEVANCE: The proposed study has important ramifications from both theoretical and patient care perspectives. Gaining understanding of interactions between the immune and central nervous system (CNS) can aid in providing etiological theories of cognitive dysfunction in CHC, as well as in other conditions in which the immune system is implicated, which then may lead to targeted interventions. Preliminary data indicate a possible role of IFN-alpha in the etiology of cognitive dysfunction, but this relationship has not been investigated specifically by examining levels of IFN-alpha in serum of patients with and without cognitive dysfunction. Further, no study has explored this relationship in patients with CHC.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 目的：本研究的中心假设是 IFN-α 是 CHC 患者认知功能障碍的关键决定因素。 该假设将通过解决以下两个具体目标来检验： 具体目标 1：检验血清中较高水平的 IFN-α 与通过神经心理学测试测量的 CHC 患者认知功能障碍相关的假设。 具体目标 2：检验以下假设：血清中较高水平的 IFN-α 与神经影像学测量的额叶皮质下网络异常相关。 研究计划：这是一项前瞻性、重复测量的研究设计，涉及 40 名 CHC 患者和 20 名健康对照 (HC) 参与者。 开始接受 IFN-α 抗病毒治疗的 CHC 患者将在基线（首次治疗后一个月内）、治疗 12、24 和 48 周后以及治疗停止后 6 个月（无论何时停止）进行评估。 HC 参与者将在相同的时间间隔接受与 CHC 患者相同的评估。 方法：尿液毒理学筛查、细胞因子测定、精神评估 (SCID-I)、神经心理学评估（注意力执行功能、信息处理/精神运动、学习/记忆、努力和心理困扰）、神经影像学（MRI、高分辨率结构 MRI、静息态 fMRI、DTI [18F]脱氧葡萄糖正电子发射断层扫描）。 临床相关性：拟议的研究从理论和患者护理的角度都具有重要的影响。 了解免疫和中枢神经系统 (CNS) 之间的相互作用有助于提供 CHC 以及涉及免疫系统的其他疾病中认知功能障碍的病因学理论，从而可能导致有针对性的干预措施。 初步数据表明 IFN-α 在认知功能障碍的病因学中可能发挥作用，但尚未通过检查患有和不患有认知功能障碍的患者血清中 IFN-α 的水平来专门研究这种关系。 此外，尚无研究探讨 CHC 患者中的这种关系。